Author

Catherine E. Gleason

Every paper listing this name carries an ORCID.

Identified by ORCID

Catherine E. GleasoniD1 paper

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Alexander SpektoriD· 1 shared Andrew T. BockusiD· 1 shared Aniruddha SarkariD· 1 shared Benedikt Mathias KessleriD· 1 shared Bernard Levin· 1 shared Bishma TuladhariD· 1 shared Breena Fraga-Walton· 1 shared Bryan M. Lent· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alexander SpektorORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity

Shilpa Singh, Catherine E. Gleason, Min Fang, Yasmin Nabil Laimon, Vishal Khivansara, Shanhai Xie, Yavuz T. Durmaz, Aniruddha Sarkar, Kenneth H. Ngo, Varunika Savla, Yixiang Li, Muhannad Abu‐Remaileh, Xinyue Li, Marie-Anaïs Locquet, Bishma Tuladhar, , Matthew G. Oser

This paper develops cyclin A/B macrocyclic inhibitors that induce apoptosis in cancers with high E2F activity by blocking RxL-mediated interactions, showing efficacy in SCLC models.

Journal of Thoracic Oncology · Aug 1, 2025Peer-reviewedCancer Biology